HIV/AIDS Treatment Trends and Progress: Where Do We Stand Today?
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
Address: 65 Peter Place
Bryanston Extension 13
2021 Republic of South Africa
Tel: +27 11 840 2300
Web: http://www.alcon.com/en/alcon-locations/africa.aspx
Founded in 1945, Alcon traces its roots back to two pharmacists, Robert Alexander and William Conner, who opened a small pharmacy in Fort Worth, Texas, and combined the first syllables of their last names to create the name Alcon.
The strengths of Alcon, CIBA VISION and Novartis Ophthalmics unite into one eye care business with Alcon becoming the second largest division of Novartis. With these collective resources and scale, Alcon offers the widest spectrum of eye care products in Surgical, Pharmaceutical and Vision Care across 180 markets and runs operations in 75 countries.
Incorporated in 1977, Alcon South Africa employs nearly 90 people focused on serving the needs of health care professionals in the area.
Alcon develops, manufactures and markets surgical equipment and devices, pharmaceuticals and vision care products in more than 180 countries. At the heart of Alcon’s ability to deliver ‘best in class’ products year after year is our Research & Development organization. All of our many engineers, scientists and medical professionals are dedicated to meeting the world’s eye health needs. In 2010, we invested USD 747 million in the pursuit of new products to enhance, preserve and restore vision. Over the next five years, Alcon plans to invest approximately USD 4 billion to discover and develop new treatment solutions for vision conditions and eye diseases.
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
Dr Benji Pretorius, the founder of Erada Technology Alliance and a malaria survivor himself, shares his insights into why the development of a truly effective malaria vaccine will only succeed…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Nevena Miletic of Roche and the IFPMA’s Africa Regulatory Network and Ian Hudson from the Bill and Melinda Gates…
The third and final piece in Lenias Hwenda of Medicines for Africa’s series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential…
The second in a three-part series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come (read part one…
In the first of a series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come, Lenias Hwenda of…
During the COVID-19 pandemic discussions around increasing access to medicines for low and middle-income countries (LMICs) were often centred on compulsory licensing. As a result, pharma companies were up in…
As part of a special focus on drug development and clinical research in Africa in February 2023’s DIA Global Forum magazine, Lisa Ursella Collins of Innomas Clinical Research, Leslie Sam…
Roughly half of Africa’s 1.1 billion people lack regular access to even the most essential medicines and most of Sub-Saharan Africa depends on imports which make up as much as…
Speaking exclusively to PharmaBoardroom, Medicines for Africa’s Lenias Hwenda gives a comprehensive overview of the African Medicines Agency, why such a regulatory body was needed, how it differs from the…
Lenias Hwenda of Medicines for Africa examines the true impact of access to medicine initiatives in Africa, noting that many of the measures takes are often cosmetic and leave a…
Some of the top pharma news coming out of South Africa including Afrigen’s partnership with US National Institutes of Health (NIH), BioNTech’s efforts to bring an mRNA start-to-finish vaccine manufacturing network…
See our Cookie Privacy Policy Here
